Press Releases SpringWorks Therapeutics, Inc.

Equities

SWTX

US85205L1070

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 11/12/2024 GMT			5-day change	1st Jan Change
39.75 ^USD	-4.52%		-6.05%	+8.90%

11-12	SpringWorks Therapeutics, Inc., Q3 2024 Earnings Call, Nov 12, 2024
11-12	Springworks Therapeutics' Q3 Net Loss Narrows	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

SpringWorks Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference	11-26	GL
SpringWorks Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference	11-26	AQ
SpringWorks Therapeutics : Reports Third Quarter 2024 Financial Results and Recent Business Highlights Form 8 K	11-12	PU
SpringWorks Therapeutics to Participate in the Jefferies London Healthcare Conference	11-12	GL
SpringWorks Therapeutics Announces Mirdametinib Data to be presented at the 2024 Society for Neuro-Oncology Annual Meeting	11-12	AQ
SpringWorks Therapeutics : Q3 2024 Earnings Presentation	11-12	PU
SpringWorks Therapeutics: Q3 Earnings Snapshot	11-12	AQ
SpringWorks Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights	11-12	GL
SpringWorks Therapeutics Announces Mirdametinib Data to be Presented at the 2024 Society for Neuro-Oncology (SNO) Annual Meeting	11-11	GL
SpringWorks Therapeutics Announces Publication of the Pivotal Phase 2b ReNeu Trial Evaluating Mirdametinib in Adults and Children with NF1-PN in the Journal of Clinical Oncology	11-11	GL
SpringWorks Therapeutics Announces Long-Term Efficacy and Safety Data from Phase 3 DeFi Trial of OGSIVEO® (nirogacestat) in Adults with Desmoid Tumors to be Presented at the Connective Tissue Oncology Society (CTOS) 2024 Annual Meeting	11-07	GL
SpringWorks Therapeutics Announces Long-Term Efficacy and Safety Data from Phase 3 DeFi Trial of OGSIVEO® (nirogacestat) in Adults with Desmoid Tumors to be Presented at the Connective Tissue Oncology Society (CTOS) 2024 Annual Meeting	11-07	AQ
SpringWorks Therapeutics to Participate in Guggenheim’s Inaugural Healthcare Innovation Conference	11-05	GL
SpringWorks Therapeutics to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024	10-22	GL
SpringWorks Therapeutics to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024	10-22	AQ
Lifordi Named Winner of Endpoints 11 as Developer of Antibody Drug Conjugates for Autoimmune and Inflammatory Diseases	09-30	AQ
FDA Grants Priority Review to SpringWorks Therapeutics’ New Drug Application for Mirdametinib for the Treatment of Adults and Children with NF1-PN	08-28	GL
SpringWorks Therapeutics: Q2 Earnings Snapshot	08-07	AQ
SpringWorks Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights	08-07	GL
SpringWorks Therapeutics Appoints Dr. Martin Mackay to its Board of Directors	07-29	GL
SpringWorks Therapeutics to Report Second Quarter 2024 Financial Results on Wednesday, August 7, 2024	07-23	GL
Kuehn Law Encourages Investors of SpringWorks, Therapeutics Inc. to Contact Law Firm	07-02	PR
SpringWorks Therapeutics Completes Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN	07-01	GL
SpringWorks Therapeutics : Termination of Material Agreement Form 8 K	06-07	PU
SpringWorks Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference	06-05	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases SpringWorks Therapeutics, Inc.

Equities

SWTX

US85205L1070

Biotechnology & Medical Research

Press Releases

Filters